Market News & Trends
Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals
Ligand Pharmaceuticals Incorporated recently announced that partner Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus…
Evonik Ramps Up Production Capacity for Biomaterials
Evonik is expanding its production facilities in Birmingham, AL, and Darmstadt, Germany. This will create additional capacity for the production of biodegradable polymers marketed globally…
MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
MilliporeSigma has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging…
Business Development Manager Needed at Fareva
Fareva is looking for a Business Development Manager/Director for the Northern American market, based in NJ, NYC, and CT, to manage its injectables/ophthalmics/high potent businesses.…
Cancer Vaccines Market Will Soar to $7.5 Billion by 2022
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth…
VWR International Acquires Reliable Biopharmaceutical Corporation & BioArra
VWR recently announced the acquisition of two companies, Reliable Biopharmaceutical and BioArra. Reliable Biopharmaceutical, a manufacturer of high-quality active pharmaceutical ingredients (APIs) and high-purity ingredients…
RedHill Biopharma Provides Update on Ongoing Phase II & III Studies
RedHill Biopharma Ltd. recently provided an update on its ongoing Phase III and Phase II clinical studies with BEKINDA for the treatment of acute gastroenteritis…
Mylan & BioCon Announce Regulatory Submission
Mylan N.V. and Biocon Ltd. recently announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for insulin glargine,…
FDA Accepts Genentech’s Biologics License Application
Halozyme Therapeutics, Inc. recently announced that the US FDA has accepted Genentech's Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer…
Evonik Industries Submits Bid for Technology Platform
Amino acids produced by fermentation are an important pillar of Evonik’s product portfolio for sustainable animal nutrition. The production processes for Biolys (lysine), ThreAMINO (threonine),…
Caris Life Sciences Designates West Virginia University Cancer Institute a Center of Excellence
Caris Life Sciences recently announced the designation of the West Virginia University (WVU) Cancer Institute as a center of excellence site in the Caris Centers…
Atara Bio to Present Results From Phase II Trial
Atara Biotherapeutics, Inc. recently announced Phase II results from its allogeneic T-cell product candidate, CMV-CTL, will be presented by its collaborating investigators at Memorial Sloan…
MorphoSys & LEO Pharma Enter Strategic Alliance
MorphoSys AG and LEO Pharma recently announced they have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
BioSun & ARTES Announce Co-Development Agreement for HPV Vaccine
BioSun Pharmed and ARTES Biotechnology recently announced they will join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran.…
Aclaris Therapeutics Submits IND Application for ATI-50001
Aclaris Therapeutics, Inc. recently announced that it has submitted an Investigational New Drug Application (IND) to the US FDA for its drug candidate ATI-50001 for…
Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion,…
Progenics Announces $50-Million Infusion to Advance Portfolio
Progenics Pharmaceuticals, Inc. recently announced its wholly owned subsidiary MNTX Royalties Sub LLC has entered into a $50-million term loan agreement with a fund managed…
Positive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder Space
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according…
Avacta Announces CAR-T Cell Therapy Research Collaboration
Avacta Group plc recently announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in novel…
Kamada Announces Plan for Phase II/III Clinical Trial
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States of its Alpha-1 Antitrypsin (G1-AAT…
